Corruption, Corporations, and Healthcare Reform

This chapter explores the implications of the recent executive order regarding the Foreign Corrupt Practices Act and its effects on American businesses abroad, critiquing the relaxation of regulations. It addresses political dynamics surrounding controversial nominations, particularly RFK Jr., and the influence of pharmaceutical companies on healthcare policies and drug pricing. The chapter emphasizes the need for bipartisan efforts to address public concerns about corruption and drug costs, reflecting a shift toward prioritizing the needs of the populace.